Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights.  

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance. ICYMI, other recent episodes include: 

“CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?” featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice; 

“Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?” featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY) 

“Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?” featuring Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate 

“Biomanufacturing: How are Industry Capacity & Supply Chains Trending?” featuring Eric Langer, MBA, Managing Partner & President, BioPlan Associates, and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates;  

“Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?”  featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice; and  

“Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead” featuring Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP.